Levosalbutamol cream - Cipher Pharmaceuticals

Drug Profile

Levosalbutamol cream - Cipher Pharmaceuticals

Alternative Names: R-salbutamol cream - Astion Pharma; ASF-1096

Latest Information Update: 24 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astion Pharma A/S
  • Developer Astion Pharma A/S; Edesa Biotech
  • Class Antiasthmatics; Bronchodilators; Ethanolamines; Phenethylamines; Skin disorder therapies; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous lupus erythematosus
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Cutaneous lupus erythematosus; Discoid lupus erythematosus
  • Preclinical Gastrointestinal disorders

Most Recent Events

  • 20 Jun 2016 Preclinical trials in Gastrointestinal disorders in Canada (unspecified route)
  • 20 Jun 2016 Levosalbutamol licensed to Edesa Biotech worldwide for the treatment of Anorectal disorders
  • 17 Apr 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top